ADVFN - Advanced Financial Network.
HOME» NASDAQ » N » NUVA Stock Price » NUVA Stock News

Nuvasive Share News

 Nuvasive (mm) Stock Price
NUVA Stock Price
 Nuvasive (mm) Stock Chart
NUVA Stock Chart
 Nuvasive (mm) Stock News
NUVA Stock News
 Nuvasive (mm) Company Information
NUVA Company Information
 Nuvasive (mm) Stock Trades
NUVA Stock Trades

NuVasive 1Q Earnings Jump; Sees Signs Of Stabilization In Spinal-Device Market

By Jon Kamp Of DOW JONES NEWSWIRES NuVasive Inc.'s (NUVA) first-quarter earnings more than doubled while the company cited glimmers of hope in a spinal-device market hurt by insurers blocking access to certain procedures. The San Diego-based company, which previously cut 2011 guidance as insurers became more aggressive, raised its full-year view Wednesday. Insurer push-back remains an issue, but surgeons are learning how to deal with this environment and it appears "the landscape is stabilizing," NuVasive Chief Executive Alex Lukianov said on a conference call. NuVasive shares were recently unchanged at $30.60 after-hours after rising earlier, and following a gain of 1.9% during regular-trading hours. Shares are up 19% on the year through Wednesday's close. Insurers have ramped up pressure on the spinal market by raising hurdles for spinal-fusion procedures for the lower back that they don't believe are well supported by medical evidence. The spinal market could also be shaken up by Johnson & Johnson's (JNJ) planned $21.3 billion purchase of medical-device maker Synthes Inc. (SYST.VX). Lukianov said NuVasive could benefit as J&J combines its existing spinal business with the acquired Synthes business; integration in that market has proven challenging before. "I think for us it's probably going to open up more opportunities," Lukianov said. "We see it as a positive for us." NuVasive reported first-quarter earnings of $2.4 million, or 6 cents a share, up from $1.09 million, or 3 cents a share, a year ago. Excluding stock-based compensation and other items, the company said earnings rose to 24 cents from 21 cents. The company also said it made an accounting change related to the economic life of fixed assets, and that this added 2 cents to per-share earnings in the recent quarter. Sales rose 14%, in the range NuVasive had projected for the quarter. Analysts surveyed by Thomson Reuters had forecast, on average, earnings of 19 cents per share on sales of $123.2 million in the recent period. Looking ahead, NuVasive said it now anticipates full-year earnings of 52 cents to 55 cents a share, up from its previous guidance for 39 cents to 42 cents. On an adjusted basis, the company raised its earnings view to $1.20 to $1.23 per share from $1.07 to $1.10 a share. The company raised its full-year sales guidance by $5 million to a range of $530 million to $540 million, implying growth of 11% to 13%. -By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com

Stock News for Nuvasive (NUVA)
DateTimeHeadline
01/15/201409:06:21U.S. Hot Stocks: Hot Stocks to Watch
11/15/201308:55:37Highbridge Capital Management 3Q 13F: Largest Eliminations
11/15/201308:55:35Highbridge Capital Management 3Q 13F: Largest Purchases
11/15/201308:55:35Highbridge Capital Management 3Q 13F: Largest Sales
11/15/201308:55:35Highbridge Capital Management 3Q 13F: Largest -2-
11/14/201307:21:26GAMCO Asset Management Inc. 3Q 13F: Largest -2-
11/14/201307:21:26GAMCO Asset Management Inc. 3Q 13F: Largest Purchases
06/12/201307:13:48NuVasive to Raise Litigation Expense After Medtronic Royalty...
10/04/201213:16:23NuVasive Shares Plunge as Customers, Sales Defect to Competitors
10/04/201209:21:09U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
06/28/201212:15:42Hospitals Surge, Insurers Slide as Health-Care Law is Upheld
01/27/201213:42:21Judge Affirms Rulings Denying Medtronic, NuVasive Motions
01/25/201216:34:24Court Denies Medtronic, NuVasive Motions Ahead of Hearing Thursday
05/04/201118:58:26NuVasive 1Q Earnings Jump; Sees Signs Of Stabilization In Spinal-Device...
04/27/201116:40:18J&J Gains Orthopedic Heft With Synthes But Faces Challenges
01/28/201116:41:27Insurer Clarifies Policy, Seen As Win For Spinal Device Makers
01/18/201117:50:48NuVasive Says Cigna, Humana Back Spine Procedure; Shares Rise
12/22/201017:15:14Medical Groups Take Issue With Insurers' Spine Surgery Rule
12/16/201009:24:31BEFORE THE BELL -2: US HOT STOCKS TO WATCH
12/01/201012:17:16NuVasive CEO Backs Views Of Spinal-Market Pressure, Outlook

Nuvasive and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad